Page last updated: 2024-11-10

valinomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3000706
CHEMBL ID223643
CHEBI ID28545
SCHEMBL ID21935101
MeSH IDM0022498

Synonyms (41)

Synonym
nsc-122023
valinomicin
valino
(3r,6r,9s,12s,15r,18r,21s,24s,27r,30r,33s,36s)-3,6,9,15,18,21,27,30,33-nonaisopropyl-12,24,36-trimethyl-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone
cyclic(d-.alpha.-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl-d-.alpha.-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl-d-.alpha.-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl )
NSC122023 ,
valinomycin
2001-95-8
cyclic(d-alpha-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl-d-alpha-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl-d-alpha-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl)
brn 0078657
hsdb 6423
antibiotic n-329 b
1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexaazacyclohexatriacontane- 2,5,8,11,14,17,20,23,26,29,32,35-dodecone, 12,24,36-trimetyl-3,6,9,15,18,21,27,30,33-nonakis(1-methylethyl)-
einecs 217-896-6
nsc 122023
chebi:28545 ,
CHEMBL223643
potassium ionophore i
4-27-00-09728 (beilstein handbook reference)
unii-n561ys75mn
n561ys75mn ,
cyclo[-d-o-val-d-val-l-o-ala-l-val]3
(3r,6r,9s,12s,15r,18r,21s,24s,27r,30r,33s,36s)-3,6,9,15,18,21,27,30,33-nonaisopropyl-12,24,36-trimethyl-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexaazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone
CCG-208283
valinomycin [hsdb]
ionophore antibiotic produced by streptomyces fulvissimus
valinomycin [mi]
cyclic(d-.alpha.-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl- d-.alpha.-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl-d-.alpha.- hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl)
cyclo(d-?-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl-d-?-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl-d-?-hydroxyisovaleryl-d-valyl-l-lactoyl-l-valyl)
AKOS024457589
bdbm50237619
DTXSID9041150
potassium ionophore i - cocktail b, selectophore(tm)
SR-05000002323-2
sr-05000002323
balinomycin
Q417504
SCHEMBL21935101
DB14057
HY-N6693
CS-0029275

Research Excerpts

Overview

Valinomycin (VLM, 1) is a K(+) ionophore cyclodepsipeptide. It is capable of depolarizing mitochondria and inducing apoptosis to several mammalian cell types, including a number of tumor cell lines.

ExcerptReferenceRelevance
"Valinomycin (VM) is a natural K"( Cation-responsive cavity expansion of valinomycin revealed by cryogenic ion trap infrared spectroscopy.
Fujii, M; Hirata, K; Ishiuchi, SI; Lisy, JM; Sato, E, 2023
)
2.62
"Valinomycin is a potent ionophore known for its ability to transport potassium ions across biological membranes. "( Theoretical investigation of hydroxylated analogues of valinomycin as potassium transporter.
Concilio, S; Diana, R; Marrafino, F; Piotto, S; Sarkar, A; Sessa, L, 2023
)
2.6
"Valinomycin is a respiratory chain inhibitor that activates mitophagy via the PINK1/Parkin signaling pathway."( Study of mitophagy and ATP-related metabolomics based on β-amyloid levels in Alzheimer's disease.
Han, TL; Li, S; Li, Y; Tang, L; Tian, M; Xiong, X; Zhang, X; Zhou, F, 2020
)
1.28
"Valinomycin (VLM, 1) is a K(+) ionophore cyclodepsipeptide capable of depolarizing mitochondria and inducing apoptosis to several mammalian cell types, including a number of tumor cell lines. "( Site-dependent biological activity of valinomycin analogs bearing derivatizable hydroxyl sites.
Abbrescia, DI; Annese, C; Catucci, L; D'Accolti, L; Denora, N; Fanizza, I; Fusco, C; La Piana, G, 2013
)
2.1
"Valinomycin is a naturally occurring cyclic dodecadepsipeptide with the formula cyclo-[D-HiVA→L-Val →L-LA→L-Val]3 (D-HiVA is D-α-hydroxyisovaleic acid, Val is valine and LA is lactic acid), which binds a K(+) ion with high selectively. "( The structure of a valinomycin-hexaaquamagnesium trifluoromethanesulfonate compound.
Bacsa, J; Fujita, M; Kazerouni, AM, 2016
)
2.21
"Valinomycin is a monovalent uniporter and does not exchange K+ for H+."( Effect of nigericin, monensin, and tetronasin on biohydrogenation in continuous flow-through ruminal fermenters.
Fellner, V; Kramer, JK; Sauer, FD, 1997
)
1.02
"Valinomycin is a potassium ionophore, and is well known to cause the collapse of the mitochondrial membrane potential. "( Valinomycin induces apoptosis of ascites hepatoma cells (AH-130) in relation to mitochondrial membrane potential.
Akiyama, J; Inai, Y; Kanno, T; Utsumi, K; Yabuki, M; Yasuda, T, 1997
)
3.18
"Valinomycin is a depsipeptide antibiotic which selectively translocates potassium across biologic membranes. "( A potassium ionophore (valinomycin) inhibits lymphocyte proliferation by its effects on the cell membrane.
Daniele, RP; Holian, SK, 1976
)
2.01
"Valinomycin is an important ionophore which exhibits a high conformational flexibility. "( Structure of valinomycin by molecular dynamics studies.
Shobana, S; Vishveshwara, S,
)
1.94
"Valinomycin is a depsipeptide antibiotic that selectively translocates potassium ion across biologic membranes. "( In vitro effect of liposome-incorporated valinomycin on growth and macromolecular synthesis of normal and ras-transformed 3T3 cells.
Daoud, SS; Juliano, RL, 1989
)
1.99
"Valinomycin is a potent inhibitor of taurine-stimulated ATP-dependent calcium ion uptake in rat retinal membrane preparations but had no effect on ATP-dependent calcium ion uptake in the absence of taurine and no effect on ATP-independent calcium ion uptake. "( Opposing interactions of ionophores (valinomycin and monensin) on calcium ion uptake in rat retinal preparations.
Lombardini, JB, 1985
)
1.98
"Valinomycin (NSC 122023) is a cyclic depsipeptide antibiotic with potassium selective ionophoric activity. "( Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
Daoud, SS; Juliano, RL, 1986
)
1.94

Effects

ExcerptReferenceRelevance
"Valinomycin has been shown to increase the amount of 8-anilino-1-naphthalenesulfonate (ANS) bound to egg lecithin liposomes and also to increase the maximum fluorescence value, as derived from double reciprocal plots. "( Transmembrane electrophoresis of 8-anilino-1-naphthalenesulfonate through egg lecithin liposome membranes.
Dawson, AP; Gains, N, 1975
)
1.7

Actions

Valinomycin did not cause a prompt inhibition of glucose-stimulated insulin release that could reflect hyperpolarization due to increased K+ permeability. The valinomycin-mediated increase in conductance was less pronounced for the S-layer-supported than for the plain GDNT-monolayer, indicating differences in the accessibility and fluidity of the lipid membranes.

ExcerptReferenceRelevance
"Valinomycin did not inhibit the oxidation of sulfur compounds."( Effects of inhibitors and NaCl on the oxidation of reduced inorganic sulfur compounds by a marine acidophilic, sulfur-oxidizing bacterium, Acidithiobacillus thiooxidans strain SH.
Higashino, E; Kamimura, K; Kanao, T; Sugio, T, 2005
)
1.05
"Valinomycin or a pH increase in the medium promote reduction of cytochrome b562 and decrease net reduction of cytochrome b566."( Control of electron transfer in the cytochrome system of mitochondria by pH, transmembrane pH gradient and electrical potential. The cytochromes b-c segment.
Capuano, F; Izzo, G; Lorusso, M; Papa, S, 1981
)
0.98
"The valinomycin-mediated increase in conductance was less pronounced for the S-layer-supported than for the plain GDNT-monolayer, indicating differences in the accessibility and/or in the fluidity of the lipid membranes."( Voltage clamp studies on S-layer-supported tetraether lipid membranes.
Pum, D; Schuster, B; Sleytr, UB, 1998
)
0.78
"Valinomycin did not inhibit translocation in the absence of K(+)."( Effects of ionophores on the phospholipid flippase activity of gastric vesicles.
Morii, M; Suzuki, H; Takeguchi, N, 1999
)
1.02
"Valinomycin did not cause a prompt inhibition of glucose-stimulated insulin release that could reflect hyperpolarization due to increased K+ permeability."( Effects of valinomycin on Rb+ fluxes, ATP content and insulin release in pancreatic islets.
Idahl, L; Sehlin, J; Täljedal, I; Tamarit-Rodriguez, J, 1978
)
1.37
"Valinomycin produces an increase of K efflux which is progressive in time and markedly dependent on the concentration of external K (0-5 mM) and valinomycin (10(-8) to 10(-5) M)."( Increase of potassium flux by valinomycin in embryonic chick heart.
Carmeliet, EE; Lieberman, M, 1975
)
1.26
"Upon valinomycin treatment, an increase in the peak at 2.8 ppm in the phosphate region (phosphocreatine set at -2.52 ppm) had been observed."( Evidence that mitochondrial phosphate is visible in 31P NMR spectra of isolated, perfused rat hearts.
Bullock, GR; Garlick, PB; Soboll, S,
)
0.59
"Valinomycin was found to increase H+-K+-ATPase activity, indicating that the second phase is because of increased proton transport rather than a decrease in proton leak rate."( Gastric H+-K+-ATPase in situ: evidence for compartmentalization.
Hersey, SJ; Matheravidathu, S; Perez, A; Sachs, G, 1989
)
1

Treatment

Valinomycin-treated CHO cells underwent several apoptotic events, including phosphatidylserine (PS) membrane translocation, caspase-3 activation, and mitochondrial membrane depolarization. EDTA was employed to estimate delta psi from 86Rb+ distribution concomitant with the delta pH for calculation of delta muH.

ExcerptReferenceRelevance
"In valinomycin-untreated cells, quercetin and O-methylated quercetin metabolite were localized in the cell membrane, whereas valinomycin treatment resulted in their uptake by the cells."( Quercetin mitigates valinomycin-induced cellular stress via stress-induced metabolism and cell uptake.
Gonzales, GB; Grootaert, C; Raes, K; Rajkovic, A; Smagghe, G; Van Camp, J; Van de Wiele, T; Vissenaekens, H, 2016
)
1.27
"Valinomycin treatment induced mitochondrial swelling and minor nuclear changes in cell lines (BV-2, C6, HEK 293), and in primary mouse microglia and astrocytes."( Perturbation of intracellular K(+) homeostasis with valinomycin promotes cell death by mitochondrial swelling and autophagic processes.
Kerschbaum, HH; Klein, B; Lütz-Meindl, U; Wörndl, K, 2011
)
1.34
"Valinomycin-treated CHO cells underwent several apoptotic events, including phosphatidylserine (PS) membrane translocation, caspase-3 activation, and mitochondrial membrane depolarization during the first few hours of exposure."( Valinomycin-induced apoptosis in Chinese hamster ovary cells.
Abdalah, R; Francis, K; Wei, L; Yu, SP, 2006
)
2.5
"Valinomycin treatment also blocks mechanically induced Ca2+ dux."( Evidence for voltage-sensitive, calcium-conducting channels in airway epithelial cells.
Boitano, S; Dirksen, ER; Woodruff, ML, 1995
)
1.01
"Valinomycin treatment caused quinine-induced swelling in bull spermatozoa to decrease rapidly to control (no quinine, no valinomycin) values, whereas in quinine-treated boar spermatozoa it had an opposite, enhancing effect."( Role of quinine-sensitive ion channels in volume regulation in boar and bull spermatozoa.
Harrison, RA; Hebel, M; Petrunkina, AM; Töpfer-Petersen, E; Weitze, KF, 2001
)
1.03
"EDTA/valinomycin treatment of cells was employed to estimate delta psi from 86Rb+ distribution concomitant with the delta pH for calculation of delta muH."( The proton electrochemical gradient in Escherichia coli cells.
Padan, E; Rottenberg, H; Zilberstein, D, 1976
)
0.71
"Upon valinomycin treatment, an increase in the peak at 2.8 ppm in the phosphate region (phosphocreatine set at -2.52 ppm) had been observed."( Evidence that mitochondrial phosphate is visible in 31P NMR spectra of isolated, perfused rat hearts.
Bullock, GR; Garlick, PB; Soboll, S,
)
0.59
"Treatment with valinomycin, a potassium ionophore, did not significantly affect nicotine uptake, indicating that nicotine uptake is an electroneutral process."( Nicotine transport in lung and non-lung epithelial cells.
Kamei, H; Kawami, M; Nagahiro, M; Takano, M; Yumoto, R, 2017
)
0.79

Toxicity

Valinomycin and cereulide are bacterial toxins with closely similar chemical structure and properties but different toxic effects. LD50 for liposome incorporated valinomycin (MVL-VM) is in excess of 50 mg/kg.

ExcerptReferenceRelevance
"7 mg/kg whereas the LD50 for liposome incorporated valinomycin (MVL-VM) is in excess of 50 mg/kg."( Reduced toxicity and enhanced antitumor effects in mice of the ionophoric drug valinomycin when incorporated in liposomes.
Daoud, SS; Juliano, RL, 1986
)
0.75
"Valinomycin and cereulide are bacterial toxins with closely similar chemical structure and properties but different toxic effects."( The higher toxicity of cereulide relative to valinomycin is due to its higher affinity for potassium at physiological plasma concentration.
Mikkola, R; Salkinoja-Salonen, MS; Saris, NE; Teplova, VV; Tonshin, AA, 2006
)
2.04
" Moreover, 4d compound did not cause toxicity to human umbilical vein endothelial cells (HUVEC), suggesting its toxic specificity to cancer cells."( Evaluation of toxicity on epithelial and tumor cells of biaryl dipeptide tyrosines.
de Vinci Kanda Kupa, L; Drewes, CC; Farsky, SH; Stefani, HA; Vasconcelos, SN, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" Impairment of glucose bioavailability reduced Rh 123 fluorescence."( Mitochondrial membrane potential measurement in rat cerebellar neurons by flow cytometry.
Camarasa, J; Camins, A; Comas, J; Escubedo, E; Gabriel, C; Sureda, FX, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" 3) Decreasing K+ efflux using K+ channel blockers (4-aminopyridine, quinine, sparteine) inhibited histamine release in a dose-response manner."( Regulation of human basophil activation. II. Histamine release is potentiated by K+ efflux and inhibited by Na+ influx.
Beauvais, F; Benveniste, J; Burtin, C; Hieblot, C; Inoue, I; Shimahara, T, 1992
)
0.28
" A dose-response curve for MPTP and its oxidized metabolite, MPP+, revealed IC50 values of 160 and 16 microM, respectively."( The neurotoxins 1-methyl-4-phenylpyridinium and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine are substrates for the organic cation transporter in renal brush border membrane vesicles.
Holohan, PD; Ross, CR; Sokol, PP, 1987
)
0.27
" The dose-response curves for three different inhibitors were identical for the OH- and Cl- gradient-stimulated modes of urate uptake."( Urate transport via anion exchange in dog renal microvillus membrane vesicles.
Aronson, PS; Kahn, AM, 1983
)
0.27
" To calculate IC50 values (the toxin concentration which determines 50% of the effect), dose-response curves were performed for each toxin."( A rapid and sensitive in vitro assay for the activity of Bacillus thuringiensis delta-endotoxins.
Belgiojoso, P; Giordana, B; Hanozet, GM; Parenti, P; Tasca, M; Villa, M, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antiviral agentA substance that destroys or inhibits replication of viruses.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
potassium ionophoreAny ionophore capable of transportation of potassium ions across membranes.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cyclodepsipeptideA depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring.
macrocycleA cyclic compound containing nine or more atoms as part of the cyclic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)3.45330.11007.190310.0000AID1443980; AID1473738; AID681139
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)3.20000.00022.318510.0000AID681153
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Km1.00000.01403.717210.0000AID681163
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (52)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (31)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (92)

Assay IDTitleYearJournalArticle
AID280245Antiproliferative activity against H460 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID521053Antimicrobial activity against Trypanosoma brucei brucei 427 bloodstream form assessed as reduction in mitochondrial membrane potential at 10 uM after 10 mins using rhodamine 123 exclusion test relative to control2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei.
AID280255Cell cycle arrest at MiaPaCa2 cells by accumulation at S phase at 10 nM after 24 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1059748Cytotoxicity against human MCF7 cells assessed as cell survival after 24 to 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1059756Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1059747Cytotoxicity against human HepG2 cells assessed as cell survival after 24 to 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1717737Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for SARS-CoV infected in African green monkey Vero E6 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID280267Cell cycle arrest in MiaPaCa2 cells by accumulation at SubG1 phase at 10 nM after 48 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1059742Selectivity ratio of IC50 for human MCF7 cells to IC50 for rat C6 cells2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID280259Cell cycle arrest in MiaPaCa2 cells by accumulation at SubG1 phase at 10 nM after 36 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1059751Cytotoxicity against human A2780 cells assessed as cell survival at 0.0001 to 10 uM by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID280269Cell cycle arrest in MiaPaCa2 cells by accumulation at G1/G0 phase at 10 nM after 48 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID421815Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Antineoplastic agents. 570. Isolation and structure elucidation of bacillistatins 1 and 2 from a marine Bacillus silvestris.
AID1059744Selectivity ratio of IC50 for human A2780 cells to IC50 for rat C6 cells2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID564970Downregulation of p27 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID280251Cell cycle arrest in MiaPaCa2 cells by accumulation at SubG1 phase at 10 nM after 24 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID99173Cross resistance profile versus L1210/R71 cells.1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID297149Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID1129875Induction of early apoptosis in human HepG2 cells assessed as decrease mitochondrial membrane potential at 0.5 uM after 4 hrs by JC-1 staining relative to control2014Journal of natural products, Apr-25, Volume: 77, Issue:4
Investigation of the cytotoxic, genotoxic, and apoptosis-inducing effects of estragole isolated from fennel (Foeniculum vulgare).
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID564971Downregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID581036Induction of bacterial membrane damage in Staphylococcus aureus ATCC 25923 at 100 uM by BacLight assay2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.
AID297150Cytotoxicity against Vero E6 cells by MTT assay2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID1059754Cytotoxicity against rat C6 cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1445792Disruption of transmembrane potential in Escherichia coli live cells harboring pores in outer membrane at 10 uM by DiSC3(5) probe-based fluorescence assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Identification and Structure-Activity Relationships of Novel Compounds that Potentiate the Activities of Antibiotics in Escherichia coli.
AID297151Selectivity index, Ratio of CC50 for Vero E6 cells to EC50 for SARS coronavirus2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID1138427Induction of collapse in deltapH in Mycobacterium smegmatis inverted membrane vesicles at 30 to 150 uM by 31P NMR spectroscopy2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
Multitarget drug discovery for tuberculosis and other infectious diseases.
AID564988Antimicrobial activity against Mycobacterium bovis BCG harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID280274Cell cycle arrest in MiaPaCa2 cells by accumulation at G1 phase at 10 nM2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID581046Induction of bacterial membrane damage in Staphylococcus epidermidis ATCC 23760 at 100 uM by BacLight assay2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.
AID297148Inhibition of SARS virus-induced cytopathogenicity in Vero E6 cells at 1 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1059733Induction of apoptosis in rat C6 cells assessed as fragmentation of mitochondrial network at 50 nM after 72 hrs by MitoTracker Red CMXRos staining-based fluorescence microscopy2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID297147Inhibition of SARS virus-induced cytopathogenicity in Vero E6 cells at 3.3 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID297145Inhibition of SARS coronavirus-induced cytopathogenicity in Vero E6 cells at 20 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID297146Inhibition of SARS coronavirus-induced cytopathogenicity in Vero E6 cells at 10 uM2007Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17
Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus.
AID1059749Cytotoxicity against human MCF7 cells assessed as cell survival at 0.0001 to 10 uM by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID421813Cytotoxicity against human KM20L2 cells after 48 hrs by sulforhodamine B assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Antineoplastic agents. 570. Isolation and structure elucidation of bacillistatins 1 and 2 from a marine Bacillus silvestris.
AID695902Inhibition of Staphylococcus aureus SA-1199B NorA expressed in Escherichia coli DH10B assessed as inhibition of Hoechst 33342 dye efflux at 10 uM by spectrofluorometric analysis in presence of 50 uM Mg2+2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID564978Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring inactivated p55 gene by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID280261Cell cycle arrest in MiaPaCa2 cells by accumulation at G1/G0 phase at 10 nM after 36 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1059734Induction of mitochondrial membrane depolarization in human MCF7 cells after 72 hrs by JC-1 staining-based FACS flow cytometric analysis (Rvb = 1%)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID372308Induction of apoptosis-like programmed cell death in Trypanosoma brucei bloodstream form assessed as loss of mitochondrial-membrane potential at 100 nM after 24 hrs by TMRE staining2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Antiproliferative effect of dihydroxyacetone on Trypanosoma brucei bloodstream forms: cell cycle progression, subcellular alterations, and cell death.
AID280273Cell cycle arrest at MiaPaCa2 cells by accumulation at G2/M phase at 10 nM after 48 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID681155TP_TRANSPORTER: increase in bodipy intracellular accumulation (Bodipy: 0.2 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID280253Cell cycle arrest in MiaPaCa2 cells by accumulation at G1/G0 phase at 10 nM after 24 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1059745Selectivity ratio of IC50 for human A2780 cells to IC50 for human HepG2 cells2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID680271TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Valinomycin: 10 uM) in MDR1-expressing NIH-3T3 cells2004Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID681163TP_TRANSPORTER: ATP hydrolysis in reconstituted proteoliposomes1996The Journal of biological chemistry, Feb-09, Volume: 271, Issue:6
Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity.
AID1059752Cytotoxicity against rat C6 cells assessed as cell survival after 24 to 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID280265Cell cycle arrest at MiaPaCa2 cells by accumulation at G2/M phase at 10 nM after 36 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1059757Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1059750Cytotoxicity against human A2780 cells assessed as cell survival after 24 to 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1059755Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1288148Induction of mitochondrial membrane potential depolarization in human SK-MEL-28 cells at 200 uM after 24 hrs by JC-1 staining based flow cytometry2016European journal of medicinal chemistry, May-23, Volume: 114Evaluation of toxicity on epithelial and tumor cells of biaryl dipeptide tyrosines.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1059741Cytotoxicity against human MCF10A cells assessed as cell survival at IC50 after 72 hrs by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID421816Cytotoxicity against human SF268 cells after 48 hrs by sulforhodamine B assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Antineoplastic agents. 570. Isolation and structure elucidation of bacillistatins 1 and 2 from a marine Bacillus silvestris.
AID1059746Cytotoxicity against human HepG2 cells assessed as cell survival at 0.0001 to 10 uM by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID681139TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP)2003Pharmaceutical research, Apr, Volume: 20, Issue:4
Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID1717738Cytotoxicity against African green monkey Vero E6 cells incubated for 2 days by the MTS assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID280249Antiproliferative activity against MCF7 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1059740Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 5 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 64.34%)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1059738Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 25.92%)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1059739Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 5 uM after 24 hrs by propidium iodide staining-based FACS flow cytometric analysis (Rvb = 9.74%)2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1717802Antiviral activity against SARS-CoV infected in African green monkey Vero E6 cells assessed as reduction in viral replication by ELISA2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID695901Inhibition of Staphylococcus aureus SA-1199B NorA expressed in Escherichia coli DH10B assessed as inhibition of Hoechst 33342 dye efflux at 10 uM after 150 to 160 secs by spectrofluorometric analysis in presence of 50 uM Mg2+2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Chalcone inhibitors of the NorA efflux pump in Staphylococcus aureus whole cells and enriched everted membrane vesicles.
AID681153TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Chemical research in toxicology, Dec, Volume: 14, Issue:12
Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
AID564968Upregulation of p27 gene expression in Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1059743Selectivity ratio of IC50 for human MCF7 cells to IC50 for human HepG2 cells2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID564969Upregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID421812Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Antineoplastic agents. 570. Isolation and structure elucidation of bacillistatins 1 and 2 from a marine Bacillus silvestris.
AID421817Cytotoxicity against human BxPC3 cells after 48 hrs by sulforhodamine B assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Antineoplastic agents. 570. Isolation and structure elucidation of bacillistatins 1 and 2 from a marine Bacillus silvestris.
AID1059753Cytotoxicity against rat C6 cells assessed as cell survival at 0.0001 to 10 uM by MTT assay2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID564983Antimicrobial activity against Mycobacterium bovis BCG KOP55 harboring pPAZ23 carrying p27-p55 operon by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID280246Antiproliferative activity against HeLa cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID421820Cytotoxicity against mouse P388 cells after 48 hrs by coulter counter method2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Antineoplastic agents. 570. Isolation and structure elucidation of bacillistatins 1 and 2 from a marine Bacillus silvestris.
AID280271Cell cycle arrest at MiaPaCa2 cells by accumulation at S phase at 10 nM after 48 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID421814Cytotoxicity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay2009Journal of natural products, Mar-27, Volume: 72, Issue:3
Antineoplastic agents. 570. Isolation and structure elucidation of bacillistatins 1 and 2 from a marine Bacillus silvestris.
AID280257Cell cycle arrest at MiaPaCa2 cells by accumulation at G2/M phase at 10 nM after 24 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID564973Antimicrobial activity against Mycobacterium bovis BCG by resazurine microtiter assay2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID606512Protonophoric activity in human HEK293T cells assessed as mitochondrial membrane depolarization at 200 uM after 10 mins by flow cytometric analysis2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Design, synthesis, and biological activities of closantel analogues: structural promiscuity and its impact on Onchocerca volvulus.
AID280247Antiproliferative activity against MiaPaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID280263Cell cycle arrest at MiaPaCa2 cells by accumulation at S phase at 10 nM after 36 hrs2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
AID1288149Induction of mitochondrial membrane potential depolarization in HUVEC at 200 uM after 24 hrs by JC-1 staining based flow cytometry2016European journal of medicinal chemistry, May-23, Volume: 114Evaluation of toxicity on epithelial and tumor cells of biaryl dipeptide tyrosines.
AID1431848Induction of mitochondrial membrane depolarization in bloodstream trypomastigote stage of wild-type Trypanosoma brucei brucei Lister 427 at 100 nM after 10 mins by TMRE dye based flow cytometry2017Journal of medicinal chemistry, 02-23, Volume: 60, Issue:4
Conjugates of 2,4-Dihydroxybenzoate and Salicylhydroxamate and Lipocations Display Potent Antiparasite Effects by Efficiently Targeting the Trypanosoma brucei and Trypanosoma congolense Mitochondrion.
AID280248Antiproliferative activity against SW620 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5
Antitumor potential of crown ethers: structure-activity relationships, cell cycle disturbances, and cell death studies of a series of ionophores.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,585)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901665 (64.41)18.7374
1990's521 (20.15)18.2507
2000's231 (8.94)29.6817
2010's145 (5.61)24.3611
2020's23 (0.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.25 (24.57)
Research Supply Index7.89 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index82.45 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews61 (2.29%)6.00%
Case Studies2 (0.07%)4.05%
Observational0 (0.00%)0.25%
Other2,604 (97.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]